Ukraine is preparing to launch a new pharmaceutical regulator. The Cabinet of Ministers has approved the creation of the Ukrainian Pharmaceutical Agency, which is expected to start operating from the beginning of 2027.
The agency will take over state control in the circulation of medicines, medical devices and blood components. The decision is part of a broader reform of medical product regulation and is intended to move Ukraine closer to the European regulatory model.
What the new agency will oversee
The regulator will work across the life cycle of medical products: development, market access, quality control, safety, efficiency and market surveillance. Its scope will also include in vitro diagnostic devices, implantable active medical devices, bioimplants, cosmetic products and controlled substances.
The reform should improve patient access to modern medicines, increase trust in legal medical products and make Ukraine more compatible with the single European regulatory space. For pharmaceutical companies, this means a more structured but also more demanding compliance environment.
The next step is to form a competition commission with Ukrainian and international experts. It will select the head of the new agency through an open process. The quality of that launch will determine whether the regulator becomes a real modernization tool for the market.
